Acutus Medical Reports Third Quarter 2023 Financial Results
- CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the third quarter of 2023.
- 11/08/2023
|
Acutus Medical Announces Strategic Realignment of Resources and Corporate Restructuring
- CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced a realignment of resources and corporate restructuring.
- 11/08/2023
|
Acutus Medical to Announce Third Quarter 2023 Financial Results
- CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
- 11/02/2023
|
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on November 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company's 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 5 individuals hired by Acutus in October 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 11/02/2023
|
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CARLSBAD, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on October 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company's 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 3 individuals hired by Acutus in September 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 10/02/2023
|
Acutus Medical, Inc. (AFIB) Q2 2023 Earnings Call Transcript
- Acutus Medical, Inc. (NASDAQ:AFIB ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 AM ET Company Participants Caroline Corner - IR David Roman - CEO Takeo Mukai - CFO Conference Call Participants Marie Thibault - BTIG John Young - Canaccord Genuity Margaret Kaczor - William Blair Operator Good day, and thank you for standing by, and welcome to the Acutus Medical Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
- 08/07/2023
|
Acutus Medical, Inc. (AFIB) Reports Q2 Loss, Tops Revenue Estimates
- Acutus Medical, Inc. (AFIB) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to earnings of $0.16 per share a year ago.
- 08/07/2023
|
Acutus Medical Reports Second Quarter 2023 Financial Results
- CARLSBAD, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023.
- 08/07/2023
|
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CARLSBAD, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on August 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company's 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 3 individuals hired by Acutus in July 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 08/01/2023
|
Acutus Medical to Present at the 43rd Annual Canaccord Growth Conference
- CARLSBAD, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the 43rd Annual Canaccord Growth Conference on Thursday, August 10, 2023 at 9:30 a.m. Eastern Time at the InterContinental Boston Hotel in Boston, MA.
- 07/27/2023
|
Acutus Medical to Announce Second Quarter 2023 Financial Results
- CARLSBAD, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its second quarter 2023 financial results on Monday, August 7, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
- 07/24/2023
|
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CARLSBAD, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on July 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company's 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 3 individuals hired by Acutus in June 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 07/03/2023
|
Acutus Medical, Inc. (AFIB) Q1 2023 Earnings Call Transcript
- Acutus Medical, Inc. (NASDAQ:AFIB ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Caroline Corner - Investor Relations David Roman - President & Chief Executive Officer Takeo Mukai - Vice President of Finance & Accounting, Interim Chief Financial Officer Conference Call Participants John Young - BTIG Marie Thibault - BTIG Operator Good afternoon and thank you for standing by. Welcome to the Acutus Medical First Quarter 2023 Conference Call.
- 05/11/2023
|
Acutus Medical to Announce First Quarter 2023 Financial Results
- CARLSBAD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
- 04/28/2023
|
Acutus Medical, Inc. (AFIB) Q4 2022 Earnings Call Transcript
- Start Time: 16:30 January 1, 0000 5:14 PM ET Acutus Medical, Inc. (NASDAQ:AFIB ) Q4 2022 Earnings Conference Call March 16, 2023, 16:30 PM ET Company Participants David Roman - President and CEO Takeo Mukai - VP, Finance & Accounting, Interim CFO Caroline Corner - IR Conference Call Participants Marie Thibault - BTIG Margaret Kaczor - William Blair William Plovanic - Canaccord Genuity Operator Thank you for standing by. Welcome to Acutus Medical's Fourth Quarter and Full Year 2022 Earnings Call.
- 03/16/2023
|
Acutus Medical, Inc. (AFIB) Q4 Earnings and Revenues Surpass Estimates
- Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 158.57% and 3.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/16/2023
|
Acutus Medical to Announce Fourth Quarter and Full Year 2022 Financial Results
- CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
- 03/09/2023
|
Acutus Medical, Inc. (AFIB) Q3 2022 Earnings Call Transcript
- Acutus Medical, Inc. (NASDAQ:AFIB ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Investor Relations David Roman - President & Chief Executive Officer Takeo Mukai - Vice President, Finance & Accounting, Interim Chief Financial Officer Conference Call Participants Marie Thibault - BTIG John Young - Canaccord Genuity Margaret Kaczor - William Blair Philip Coover - Goldman Sachs Javier Fonseca - Spartan Capital Operator Good day, and thank you for standing by. Welcome to the Acutus Medical Third Quarter 2022 Earnings Call.
- 11/13/2022
|
Acutus Medical, Inc. (AFIB) Reports Q3 Loss, Tops Revenue Estimates
- Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 13.25% and 3.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2022
|
Acutus Medical to Announce Third Quarter 2022 Financial Results
- CARLSBAD, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2022 financial results on Thursday, November 10, 2022. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
- 10/27/2022
|
Acutus Medical, Inc. (AFIB) CEO David Roman on Q2 2022 Results - Earnings Call Transcript
- Acutus Medical, Inc. (NASDAQ:AFIB ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Caroline Corner - Investor Relations David Roman - Chief Executive Officer & Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Allen Gong - JPMorgan Marie Thibault - BTIG Javier Fonseca - Spartan Capital John Young - Canaccord Operator Good day and welcome to the Acutus Medical Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 08/12/2022
|
Acutus Medical to Announce Second Quarter 2022 Financial Results
- CARLSBAD, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its second quarter 2022 financial results on Thursday, August 11, 2022. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
- 07/28/2022
|
Why Is Acutus Medical (AFIB) Stock Up 100% Today?
- AFIB stock traders are celebrating as the FDA clears its arrhythmia management product for commercialization. The post Why Is Acutus Medical (AFIB) Stock Up 100% Today?
- 06/27/2022
|
Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving
- Penny stocks to watch with news The post Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/27/2022
|
Why Acutus Medical Shares Are Rallying Today?
- Acutus Medical Inc (NASDAQ: AFIB) has launched an expanded suite of left-heart access products, including the AcQCross Qx system for use with the TruSeal and FXD delivery system for the Watchman LAAC Device. AcQCross is a transseptal system engineered with an integrated needle and.
- 06/27/2022
|
Acutus Medical, Inc. (AFIB) CEO Vince Burgess on Q2 2022 Results - Earnings Call Transcript l: ZIP
- Acutus Medical, Inc. (NASDAQ:AFIB ) Q2 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Caroline Corner - IR Scott Huennekens - Chairman David Roman - Interim CEO and CFO Conference Call Participants Brandon Vazquez - William Blair Marie Thibault - BTIG Bill Plovanic - Canaccord Genuity Javier Fonseca - Spartan Capital Operator Thank you for standing by and welcome to the Acutus Medical, Inc. First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 05/12/2022
|
Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates
- Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -1.01% and 29.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/12/2022
|
3 Hot Trending Penny Stocks to Watch in May 2022
- Check these trending penny stocks out for your watchlist The post 3 Hot Trending Penny Stocks to Watch in May 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/01/2022
|
Acutus Medical to Announce First Quarter 2022 Financial Results
- CARLSBAD, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its first quarter 2022 financial results on Thursday, May 12, 2022. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
- 04/27/2022
|
Acutus Medical Stock Soars On Debt Refinancing, Divestiture Of Left-Heart Access Portfolio
- Acutus Medical Inc (NASDAQ: AFIB) shares are skyrocketing on a commitment letter from Deerfield Management Company to refinance its existing debt with a new longer-term credit facility. The Company has also agreed to sell its left-heart access portfolio to Medtronic plc (.
- 04/27/2022
|
Best Penny Stocks to Buy Today? 3 Climbing In Morning Trading
- Here's what you need to know about trading penny stocks on April 27th The post Best Penny Stocks to Buy Today? 3 Climbing In Morning Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/27/2022
|
5 Top Biotech Penny Stocks Under $1 To Watch This Week
- Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/19/2022
|
Acutus Medical to Present at the 21st Annual Needham Virtual Healthcare Conference
- CARLSBAD, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:45 p.m. Eastern Time.
- 03/31/2022
|
Here's Why Acutus Medical Shares Are Falling
- Acutus Medical Inc (NASDAQ: AFIB) shares are trading lower by 20.8% at $1.53 after the company reported worse-than-expected fourth-quarter EPS results and issued first-quarter sales guidance below analyst estimates. Acutus Medical reported quarterly losses of $1.00 per share which missed the.
- 03/31/2022
|
Acutus Medical, Inc. (AFIB) CEO Vince Burgess on Q4 2021 Results - Earnings Call Transcript
- Acutus Medical, Inc. (AFIB) CEO Vince Burgess on Q4 2021 Results - Earnings Call Transcript
- 03/30/2022
|
Acutus Medical, Inc. (AFIB) Reports Q4 Loss, Tops Revenue Estimates
- Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -8.70% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/30/2022
|
Acutus Medical to Announce Fourth Quarter and Full-Year Financial Results
- CARLSBAD, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its fourth quarter and full-year 2021 financial results on Thursday, March 17, 2022. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
- 03/10/2022
|
A Duo of Net Current Asset Value Stocks to Consider
- There are some investors who buy U.S.-listed stocks that are trading below their liquidation values because they believe they can gain a lot from these stocks after the market has reappraised the share prices to near or above the liquidation value.
- 01/12/2022
|
Acutus Medical (AFIB) Stock: Why The Price Dropped Today
- The stock price of Acutus Medical Inc (NASDAQ: AFIB) fell over 25% pre-market today. This is why it happened.
- 11/12/2021
|
Acutus Medical's (AFIB) CEO Vince Burgess on Q3 2021 Results - Earnings Call Transcript
- Acutus Medical's (AFIB) CEO Vince Burgess on Q3 2021 Results - Earnings Call Transcript
- 11/11/2021
|
Recap: Acutus Medical Q3 Earnings
- Acutus Medical (NASDAQ:AFIB) reported its Q3 earnings results on Thursday, November 11, 2021 at 04:01 PM. Here's what investors need to know about the announcement.
- 11/11/2021
|
Analysts Estimate Acutus Medical, Inc. (AFIB) to Report a Decline in Earnings: What to Look Out for
- Acutus Medical, Inc. (AFIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/04/2021
|
Acutus Medical, Inc. (AFIB) Moves 9.6% Higher: Will This Strength Last?
- Acutus Medical, Inc. (AFIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 09/28/2021
|
Acutus Medical: A Name To Slowly Accumulate
- Acutus Medical, Inc.'s superior contactless mapping technology threatens to change and expand the ablation treatment paradigm for cardiac arrhythmias. However, the company's launch has been disappointing with the pandemic being held out as the scapegoat.
- 09/04/2021
|
Acutus Medical, Inc. (AFIB) CEO Vince Burgess on Q2 2021 Results - Earnings Call Transcript
- Acutus Medical, Inc. (AFIB) CEO Vince Burgess on Q2 2021 Results - Earnings Call Transcript
- 08/12/2021
|
Acutus Medical, Inc. (AFIB) Reports Q2 Loss, Tops Revenue Estimates
- Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 11.00% and 1.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/12/2021
|
Acutus Medical, Inc.: Paradigm-Shifting Technology At A Shocking Price
- Acutus Medical, Inc.: Paradigm-Shifting Technology At A Shocking Price
- 07/21/2021
|
Acutus Medical, Inc. Announces Pricing of Public Offering of Common Stock
- CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Nasdaq: AFIB) (“Acutus”) today announced the pricing of its underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares of common stock are being offered by Acutus. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Acutus, are expected to be $77.0 million. The offering is expected to close on July 19, 2021, subject to the satisfaction of customary closing conditions. In addition, Acutus has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of Acutus' common stock at the price to the public, less underwriting discounts and commissions.
- 07/14/2021
|
Acutus Medical, Inc. Announces Proposed Public Offering of Common Stock
- CARLSBAD, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today announced it has commenced an underwritten public offering of 5,500,000 shares of its common stock. All of the shares of common stock are being offered by Acutus. In addition, Acutus expects to grant the underwriters a 30-day option to purchase up to an additional 825,000 shares of its common stock in the offering.
- 07/12/2021
|
Acutus Medical Reports Preliminary Unaudited Second Quarter 2021 Financial Results
- CARLSBAD, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported preliminary unaudited results for the second quarter of 2021.
- 07/12/2021
|
Acutus Medical Receives Green Signal From FDA To Start AcQBlate Atrial Fibrillation Trial
- The FDA has signed off Investigational Device Exemption (IDE) AcQBlate AF trial for Acutus Medical Inc's (NASDAQ: AFIB) AcQBlate Force Sensing Ablation Catheter and System. The trial is expected to enroll 350 subjects and evaluate the system's safety and efficacy in the treatment of both paroxysmal and persistent atrial fibrillation.
- 05/27/2021
|
Acutus Medical to Present at the 41st Annual William Blair Growth Stock Conference
- CARLSBAD, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will participate at the 41st Annual William Blair Growth Stock Conference on Thursday, June 3, 2021 at 12:20 p.m. Eastern Time.
- 05/20/2021
|
Acutus Medical, Inc. (AFIB) CEO Vince Burgess on Q1 2021 Results - Earnings Call Transcript
- Acutus Medical, Inc. (AFIB) CEO Vince Burgess on Q1 2021 Results - Earnings Call Transcript
- 05/12/2021
|
Acutus Medical to Announce First Quarter 2021 Financial Results
- CARLSBAD, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the first quarter of 2021 on Wednesday, May 12, 2021. In conjunction with the release, Acutus will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
- 04/28/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acutus Medical, Inc. - AFIB
- NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ: AFIB). Such investors are advised to contact Robert S.
- 04/06/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acutus Medical, Inc. - AFIB
- New York, New York--(Newsfile Corp. - March 31, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ: AFIB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Acutus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 03/31/2021
|
Acutus Medical to Present at the 20ᵗʰ Annual Needham Virtual Healthcare Conference
- CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 3:45 p.m. Eastern Time.
- 03/30/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acutus Medical, Inc. - AFIB
- NEW YORK, March 30, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ: AFIB). Such investors are advised to contact Robert S.
- 03/30/2021
|
Acutus Medical to Announce Fourth Quarter and Full Year 2020 Financial Results
- CARLSBAD, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the fourth quarter and full year of 2020 on Thursday, March 18, 2021. In conjunction with the release, Acutus will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
- 03/04/2021
|
Acutus Medical Receives Vizient Innovative Technology Contract
- Contract Pricing Now Widely Available for the AcQMap® High Resolution 3D Imaging and Mapping System Contract Pricing Now Widely Available for the AcQMap® High Resolution 3D Imaging and Mapping System
- 03/02/2021
|
Acutus Medical to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
- CARLSBAD, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021 at 2:00 p.m. Eastern Time.
- 02/04/2021
|
U.S. IPO Week Ahead: Canadian IT And German Chemicals Lead A Diverse 9-IPO Week
- U.S. IPO Week Ahead: Canadian IT And German Chemicals Lead A Diverse 9-IPO Week
- 01/30/2021
|
Acutus Medical Reports Preliminary, Unaudited Fourth Quarter and Full Year 2020 Results
- CARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported preliminary unaudited revenue results for the quarter and full year ended December 31, 2020.
- 01/13/2021
|
Acutus Medical to Present at the J.P. Morgan 39th Annual Healthcare Conference
- CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that its management will present at the upcoming J.P. Morgan 39th Annual Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. Eastern Time.
- 12/28/2020
|
What Insiders Have To Say About This All-Time High - August 2020 Insider Update
- Insider activity is very informative to follow up for two reasons: it can help predict future market movements and it can be interesting to find undervalued stocks.
- 09/05/2020
|
Wall Street Breakfast: The Week Ahead
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 08/30/2020
|
Acutus Medical Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- CARLSBAD, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), today announced the closing of its initial public offering of 10,147,058 shares of common stock, which includes the exercise in full of the underwriters’ option to purchase 1,323,529 additional shares of its common stock, at a price to the public of $18.00 per share. All of the shares were offered by Acutus. The aggregate gross proceeds to Acutus from the offering were approximately $182.6 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Select Market on August 6, 2020 under the symbol “AFIB”. J.P. Morgan and BofA Securities acted as joint book-running managers. William Blair acted as book-running manager. Canaccord Genuity and BTIG acted as co-managers.Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on August 5, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.About Acutus Medical, Inc. Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.Investor Contact: Caroline Corner Westwicke ICR D: 415-314-1725 Caroline.corner@westwicke.com Holly Windler M: 619-929-1275 media@acutusmedical.com Caution Regarding Forward-Looking Statements This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States, including changes in government reimbursement of procedures, dependence upon third-party vendors, timing of regulatory approvals, the impact of the recent coronavirus (COVID-19) pandemic and our response to it, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
- 08/10/2020
|
Acutus Medical Announces Pricing of Initial Public Offering
- CARLSBAD, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (NASDAQ: AFIB) today announced the pricing of its initial public offering of 8,823,529 shares of its common stock at a price to the public of $18.00 per share. All of the shares are being offered by Acutus. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Acutus, are expected to be approximately $158.8 million. The shares are expected to begin trading on The Nasdaq Global Select Market on August 6, 2020, under the symbol “AFIB.” The offering is expected to close on August 10, 2020, subject to the satisfaction of customary closing conditions. In addition, Acutus has granted the underwriters a 30-day option to purchase up to an additional 1,323,529 shares of Acutus’ common stock at the initial public offering price, less the underwriting discounts and commissions. J.P. Morgan and BofA Securities are acting as joint book-running managers. William Blair is also acting as book-running manager. Canaccord Genuity and BTIG are acting as co-managers.Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on August 5, 2020. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.About Acutus Medical, Inc. Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.Investor Contact: Caroline Corner Westwicke ICR D: 415-314-1725 Caroline.corner@westwicke.comHolly Windler M: 619-929-1275 media@acutusmedical.com Caution Regarding Forward-Looking Statements This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. These forward-looking statements include, without limitation, references to Acutus’ expectations regarding the commencement of trading on The Nasdaq Global Select Market and the completion, timing and size of the public offering. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, risks and uncertainties related to completion of the public offering and the satisfaction of customary closing conditions related to the public offering. Additional factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States, including changes in government reimbursement of procedures, dependence upon third-party vendors, timing of regulatory approvals, the impact of the recent coronavirus (COVID-19) pandemic and our response to it, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
- 08/06/2020
|
IPO Update: Acutus Medical Proposes IPO Terms
- Acutus Medical intends to raise $125 million in an IPO of its common stock. The firm is developing and commercializing cardiac ablation tools.
- 07/31/2020
|
Acutus Medical Files For IPO For Commercialization Push
- Acutus Medical has filed to raise $75 million in a U.S. IPO, although the final figure may differ.
- 07/23/2020
|
U.S. IPO Weekly Recap: nCino Pops 195% In 8-IPO Week
- Eight IPOs and six SPACs entered public markets this past week, led by nCino, which soared 195% in the biggest first-day pop for a US tech company in nearly 20 years.
- 07/18/2020
|
